Therapy Detail

Therapy Name SNX-5422
Synonym
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SNX-5422 PF-04929113 HSP90 Inhibitor 35 SNX-5422 is the prodrug of the potent Hsp90 inhibitor SNX-2112, which has been shown to decrease activation Her-2, Akt, and ERK, inhibit tumor cell proliferation, and induce tumor cell apoptosis (PMID: 21349995, PMID: 18948577).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02063958 Phase I SNX-5422 Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors Completed
NCT02612285 Phase II SNX-5422 Study of SNX-5422 in TP53 Null Cancers Terminated
NCT01848756 Phase Ib/II SNX-5422 Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Terminated
NCT01635712 Phase I SNX-5422 Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies Completed
NCT01892046 Phase I Carboplatin SNX-5422 Paclitaxel Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Completed